Ferring Pharmaceuticals is a global biopharmaceutical company based in Saint-Prex, Switzerland. It was founded in 1950 by Frederik Paulsen. Ferring focuses on researching, developing, and producing innovative treatments in reproductive medicine and maternal health, urology, gastroenterology, endocrinology, and orthopedics.

The company's headquarters in Saint-Prex is a state-of-the-art research and development center, housing scientists and researchers working on new therapeutic solutions. Ferring also has manufacturing facilities in several countries, including Denmark, Germany, Israel, China, and Brazil. Ferring offers a range of products, including fertility treatments, hormone therapies, gastroenterology medications, and innovative drugs for orthopedic and urological conditions.

Its most well-known product is MENOPUR®, a fertility medication used for the stimulation of ovulation in women undergoing assisted reproductive techniques. Operating on a global scale, Ferring has established subsidiaries and offices in more than 60 countries, with a presence in Europe, North America, Latin America, Asia-Pacific, Middle East, and Africa. In addition to its own operations, Ferring collaborates with numerous academic institutions, biotech companies, and other pharmaceutical companies through joint ventures and partnerships to accelerate the development and delivery of groundbreaking therapies.

Ferring has a strong market position and is recognized as a leader in several therapeutic areas. It has experienced significant growth over the years and has achieved global sales of over $2 billion. The company's dedication to research and development, along with its commitment to patient care, has allowed it to compete against other pharmaceutical giants.

In recent years, Ferring has made strategic acquisitions and collaborations to expand its product portfolio and increase its presence in key markets. In 2020, the company acquired FerGene, a gene therapy company focused on the treatment of bladder cancer. Currently, Ferring continues to invest in research and development to bring new treatments to market.

It remains committed to improving the lives of patients worldwide through innovative therapies and ongoing collaborations with industry partners